Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review

Recently approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations (e.g., capmatinib, tepotinib) are a new and important therapeutic option for the treatment of non-small cell lung cancer (NSCLC) patients harbouring c-MET alterations. Several experimental studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Dempke, Wolfram C. M., Fenchel, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264346/
https://www.ncbi.nlm.nih.gov/pubmed/34295669
http://dx.doi.org/10.21037/tlcr-21-124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264346/
https://www.ncbi.nlm.nih.gov/pubmed/34295669
http://dx.doi.org/10.21037/tlcr-21-124

Ejemplares similares